ATE469159T1 - Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten - Google Patents

Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten

Info

Publication number
ATE469159T1
ATE469159T1 AT06708618T AT06708618T ATE469159T1 AT E469159 T1 ATE469159 T1 AT E469159T1 AT 06708618 T AT06708618 T AT 06708618T AT 06708618 T AT06708618 T AT 06708618T AT E469159 T1 ATE469159 T1 AT E469159T1
Authority
AT
Austria
Prior art keywords
antagonistic activity
combined
undecanone
derivatives
pain
Prior art date
Application number
AT06708618T
Other languages
English (en)
Inventor
Frans Eduard Janssens
Sophie Coupa
A Ph Poncelet
Bruno Schoentjes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE469159T1 publication Critical patent/ATE469159T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06708618T 2005-03-03 2006-03-03 Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten ATE469159T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101657 2005-03-03
PCT/EP2006/060419 WO2006094934A1 (en) 2005-03-03 2006-03-03 Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists

Publications (1)

Publication Number Publication Date
ATE469159T1 true ATE469159T1 (de) 2010-06-15

Family

ID=34938877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06708618T ATE469159T1 (de) 2005-03-03 2006-03-03 Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten

Country Status (15)

Country Link
US (1) US8138334B2 (de)
EP (1) EP1874783B1 (de)
JP (1) JP5094422B2 (de)
KR (1) KR101355064B1 (de)
CN (1) CN101133064B (de)
AT (1) ATE469159T1 (de)
AU (1) AU2006222061B2 (de)
BR (1) BRPI0608074A2 (de)
CA (1) CA2598530C (de)
DE (1) DE602006014531D1 (de)
EA (1) EA012421B1 (de)
ES (1) ES2346147T3 (de)
MX (1) MX2007010728A (de)
NZ (1) NZ556629A (de)
WO (1) WO2006094934A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP3915560A1 (de) 2014-06-25 2021-12-01 Emory University Verfahren zur bewältigung von bedingter angst mit neurokinin-rezeptor-antagonisten
KR101579688B1 (ko) 2014-07-08 2015-12-24 재단법인 전남생물산업진흥원 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물
EP3704271B1 (de) 2017-11-02 2026-01-28 California Institute of Technology Neurokinin-antagonisten und verwendung davon
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
EP4181928A4 (de) * 2020-07-18 2024-07-03 Hoth Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von lungenentzündung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
EP1023065A1 (de) 1997-08-29 2000-08-02 Dsm N.V. Zusatzfreie granulate
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
DK1308439T3 (da) * 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
EP1390372B1 (de) * 2001-05-14 2008-07-16 F. Hoffmann-La Roche Ag 1-OXA-3,9-DIAZASPIROç5.5]UNDECAN-2-ONDERIVATE UND DEREN VERWENDUNG ALS ANTAGONISTEN DES NEUROKININREZEPTORS
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
KR20060006098A (ko) * 2003-06-10 2006-01-18 얀센 파마슈티카 엔.브이. 오피오이드 진통제와 배합된 치환된1,4-디-피페리딘-4-일-피페라진 유도체 및 오피오이드계치료와 관련된 통증 및 부작용 치료용으로 이들의 용도
KR100863854B1 (ko) * 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제

Also Published As

Publication number Publication date
US20100292228A1 (en) 2010-11-18
EP1874783A1 (de) 2008-01-09
CA2598530A1 (en) 2006-09-14
KR101355064B1 (ko) 2014-01-24
ES2346147T3 (es) 2010-10-11
EA012421B1 (ru) 2009-10-30
JP2008531659A (ja) 2008-08-14
US8138334B2 (en) 2012-03-20
NZ556629A (en) 2010-04-30
EA200701879A1 (ru) 2008-02-28
DE602006014531D1 (de) 2010-07-08
CN101133064A (zh) 2008-02-27
AU2006222061A1 (en) 2006-09-14
BRPI0608074A2 (pt) 2009-11-03
CA2598530C (en) 2014-12-16
AU2006222061B2 (en) 2011-04-28
JP5094422B2 (ja) 2012-12-12
MX2007010728A (es) 2007-10-12
CN101133064B (zh) 2011-02-23
WO2006094934A8 (en) 2006-12-07
WO2006094934A1 (en) 2006-09-14
EP1874783B1 (de) 2010-05-26
KR20070113224A (ko) 2007-11-28

Similar Documents

Publication Publication Date Title
TW200604198A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
JO2527B1 (en) Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
TW200603797A (en) Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
TNSN08104A1 (en) Pyrimidine amide compounds as pgds inhibitors
WO2004056799A3 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
NZ561747A (en) (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity
DE602006014531D1 (de) Substituierte oxadiazaspiro-ä5.5ü-undecanonderivate und ihre verwendung als neurokininantagonisten
MX2009013885A (es) Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico.
EA200601868A1 (ru) 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов
MX2009005507A (es) Derivados de espiro-piperidina.
MX2011009700A (es) Derivado de amida.
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
MX2009006454A (es) Derivados de espiro-piperidina.
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
MX2009005544A (es) Indoles.
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
ATE478075T1 (de) Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
WO2006011024A3 (en) New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
MX2009006446A (es) Derivados de espiro-piperidina.
EA200801342A1 (ru) 3-(4-{[4-(4-{[3-(3,3-диметил-1-пиперидинил)пропил]окси}фенил)-1-пиперидинил]карбонил}-1-нафталинил)пропановая или пропеновая кислота в качестве антагонистов н1 и н3-рецепторов для лечения воспалительных и аллергических расстройств
TW200700390A (en) Metabolites for nk-1 antagonists for emesis
JO2485B1 (en) 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
MY145168A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
ATE438620T1 (de) Azetidin-derivate als ccr-3-rezeptor-antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties